

13 February 2026

## Osteopore strikes partnership with Medprin for Latin America

### Highlights

- Osteopore strengthens its distribution line-up for Latin America through an exclusive partnership with Medprin Biotech GmbH, a fully-owned subsidiary of Medprin Regenerative Medical Technologies Co., Ltd, a listed company on the ChiNext market of the Shenzhen Stock Exchange (301033.SZ).
- The business will focus on the craniofacial reconstruction market in Latin America – the most developed product segment at Osteopore.

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the partnership with Medprin Biotech GmbH, a fully-owned subsidiary of Medprin Regenerative Medical Technologies Co., Ltd (301033.SZ), a neurosurgery-focused company listed on the ChiNext market of the Shenzhen Stock Exchange with a market capitalisation of approximately RMB 4.9 billion<sup>1</sup> (~AUD 1.0 billion), for the Latin American craniofacial reconstruction market.

The Latin American market consists of 20 countries, including Argentina, Chile, Colombia and Mexico, and represents a strategically important and emerging growth opportunity for Osteopore in the areas of neurosurgery, orbital reconstruction and maxillofacial trauma.

<sup>1</sup> At the time of this announcement.

Latin America's healthcare landscape presents a unique commercial opportunity for Osteopore's advanced bone regenerative devices through its dual public-private system, with private hospitals and tertiary centres delivering a larger share of complex surgical care relative to their size<sup>2</sup>.

According to published market research reports, the Latin America craniomaxillofacial market was valued at USD 260m (~AUD 367m) in 2023 and is predicted to reach USD 360m (~AUD 509m) at a Compound Annual Growth Rate (CAGR) of 7.13% between 2023 and 2028<sup>3</sup>.

With Medprin as Osteopore's partner, access is expected to be significantly enhanced from one country (Colombia)<sup>4</sup> to the region, which consists of 20 countries. Full commercial access to the region is expected to occur in phases and over a period of time due to product registration requirements.

This latest progress complements Osteopore's growing footprint in this emerging market, including the distribution arrangement in Brazil<sup>5</sup> and the Company's technology development collaboration with the University of Chile<sup>6</sup>.

#### **Key terms:**

- 3-year distribution agreement with the option of a 1-year extension subject to mutual agreement
- Territory assigned: Latin America (excluding Brazil)

<sup>2</sup> [https://www.delvens.com/blog/views-regarding-medical-care-in-latin-america?utm\\_source=chatgpt.com](https://www.delvens.com/blog/views-regarding-medical-care-in-latin-america?utm_source=chatgpt.com)

<sup>3</sup> <https://www.marketdataforecast.com/market-reports/latin-america-craniomaxillofacial-implants-market>

<sup>4</sup> ASX announcement, "OSX Expands to Latin America with Initial Sales to Colombia" 7 April 2022.

<sup>5</sup> ASX announcement, "Osteopore Secures Brazilian Craniofacial Distribution Deal" 24 October 2024.

<sup>6</sup> ASX announcement, "OSX and University of Chile complete bone implant studies" 22 August 2024.

- Business area: Craniofacial reconstruction
- Standard non-performance termination clauses relating to revenue apply

**Commenting on the partnership with Medprin, CEO Dr Yujing Lim, said:**

"The Latin American market represents a unique growth opportunity for us, and we are delighted to partner with Medprin, a company specialised in neurosurgery and craniofacial surgery", said Dr Lim.

**Commenting on the partnership with Osteopore, Medprin Director of International Business, Henzer Guo, said:**

"Osteopore has a unique product and technology that we believe is the future of surgery – regenerative medicine. We believe this is an excellent collaboration that leverages our existing channels to reach patients efficaciously", said Mr. Guo.

**ENDS**

*This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**

Executive Chairman

Osteopore Limited

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

### **About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### **About Medprin Regenerative Medical Technologies Co., Ltd**

Medprin is short for "Medical Printing". Medprin specializes in research, development, and manufacturing of the high-end medical devices, with successful technology transformation of Class III implantable medical devices such as ReDura™, NeoDura™, and Recranio™, etc.. Products are available in more than 100 countries and regions and have benefited more than 1,600,000 patients.

### **Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.